Searchable abstracts of presentations at key conferences in endocrinology

ea0022p416 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma characterized for plasma mitotane level and ERCC1 protein expression analyses

Malandrino Pasqualino , Ghuzlan Abir Al , Castaing Marine , Young Jacques , Caillou Bernard , Travagli Jean-Paul , Elias Dominique , de Baere Thierry , Dromain Clarisse , Chanson Philippe , Schlumberger Martin , Leboulleux Sophie , Baudin Eric

Introduction: Mitotane and platinum-based chemotherapy are the main therapeutic choices for treating inoperable and/or metastatic adrenocortical carcinoma (ACC).Objective: To search for prognostic parameters of survival in patients with metastatic ACC treated with combined mitotane- and platinum-based chemotherapy.Patients: One hundred and thirty one consecutive patients with metastatic ACC treated at the Gustave-Roussy Institute (...